ADXS Research and Charts

ADXS - Advaxis Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-26 (Delayed quote data 2025-03-27)

Last 0.03	Change ⇓ 0.00 (0.00%)	Volume 81
	Open 0.03	High 0.03	Low 0.03

8EMA (Daily) 0.03	40EMA (Daily) 0.03	50EMA (Daily) 0.03	STO (Daily) 0.000	MACD Hist (Daily) 0.000
8EMA (Weekly) 0.035	40EMA (Weekly) 0.13	50EMA (Weekly) 0.18	STO (Weekly) 0.000	MACD Hist (Weekly) 0.020


Company Profile
Advaxis Inc is a clinical stage biotechnology company operating in the United States. It focuses on the discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology which utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate Specific Antigen (PSA) associated with prostate cancer.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.